Abstract
Despite the numerous uses of chitin and chitosan as new functional materials of high potential in various fields, they are still behind several directly compressible excipients already dominating pharmaceutical applications. There are, however, new attempts to exploit chitin and chitosan in co-processing techniques that provide a product with potential to act as a direct compression (DC) excipient. This review outlines the compression properties of chitin and chitosan in the context of DC pharmaceutical applications.
Highlights
The exploitation of new techniques in pharmaceutical processing has given preferential emphasis to the use of direct compression (DC) over wet granulation approaches to tablet production
Chitin and chitosan have been widely acknowledged as effective tablet disintegrants due to their high water absorption capacity
In a related study presented by Katharina et al wherein they investigated the slope of the Heckel function for different molecular weight (MW) chitosans, chitosan with a MW of 87.2 kDa behaves in a manner similar to Avicel® PH 102, and the others with 173.3 and 210.5 kDa showed a lower Heckel slope and higher resistance against deformation [86]
Summary
The exploitation of new techniques in pharmaceutical processing has given preferential emphasis to the use of DC over wet granulation approaches to tablet production. The second one is the complexity of the powder modification process for the. Some processes represent highly effective techniques for powder modification that suit DC applications, e.g., spray drying [2]. It is industrially desirable to utilize, for example, roll compaction for powder consolidation as an effective approach for dry granulation [3]. Few excipients can be directly compressed into tablets, owing to detrimental physical properties such as poor compactibility, flowability, and compressibility [5]. There is a need to improve such properties by physical or chemical co-processing modifications [6]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
